(E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE

Base Information

• Chemical Name: (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE
• CAS No.: 658084-64-1
• Deprecated CAS: 1198425-96-5
• Molecular Formula: C24H29N3O2
• Molecular Weight: 391.513
• Hs Code.: 2933399990
• European Community (EC) Number: 684-724-8,864-731-4
• UNII: V71TF6V9M7
• DSSTox Substance ID: DTXSID101026050
• Nikkaji Number: J2.349.584H
• Wikidata: Q27076984
• NCI Thesaurus Code: C67043
• Pharos Ligand ID: XKWR2PMXPJ3U
• Metabolomics Workbench ID: 153667
• ChEMBL ID: CHEMBL566757
• Mol file: 658084-64-1.mol

Synonyms:(E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE;2-PROPENAMIDE, N-[4-(1-BENZOYL-4-PIPERIDINYL)BUTYL]-3-(3-PYRIDINYL)-, (2E)-;FK 866;APO-866;K 22.175;(2E)-N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide;FK866 (APO866);FK866 (APO866, Daporinad)

Chemical Property of (E)-N-[4-(1-BENZOYL-PIPERIDIN-4-YL)-BUTYL]-3-PYRIDIN-3-YL-ACRYLAMIDE

Chemical Property:

• Boiling Point: 629.9±51.0 °C(Predicted)
• PKA: 14.12±0.46(Predicted)
• PSA: 62.30000
• Density: 1.131
• LogP: 4.26250
• Storage Temp.: ?20°C
• Solubility.: DMSO: soluble10mg/mL, clear
• XLogP3: 3.7
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 8
• Exact Mass: 391.22597718
• Heavy Atom Count: 29
• Complexity: 534

Purity/Quality:

99% ^*data from raw suppliers

FK 866 hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 22

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: C1CN(CCC1CCCCNC(=O)C=CC2=CN=CC=C2)C(=O)C3=CC=CC=C3
• Isomeric SMILES: C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3
• Recent ClinicalTrials: A Study to Assess APO866 for the Treatment of Advanced Melanoma
• Recent EU Clinical Trials: A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma
• Description: Daporinad (FK866, APO866) effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM in a cell-free assay. Phase 1/2. FK-866 is a highly specific non-competitive inhibitor of Nampt (Ki = 0.4 nM), causing gradual NAD+ depletion. In HepG2 human liver carcinoma cells, NAD+ depletion by FK-866 directs delayed cell death by apoptosis (IC50 = ~1 nM). In normal human smooth muscle cells, FK-866 causes premature senescence, an effect that may be linked to decreased activity of the NAD+-dependent enzyme SIRT1. Also, FK-866 induces autophagy in SH-SY5Y neuroblastoma cells, as indicated by the formation of LC3-positive vesicles.
• Uses: FK866 hydrochloride hydrate has been used:to investigate its effects on intra-axonal NAD+ levelsto induce NAD+ depletionto reduce the level of tumor necrosis factor-α (TNF-α), nicotinamide phosphoribosyltransferase (NAMPT) and interleukin-6 (IL-6) in the ischemic brain tissue